Opinion

Video

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

Video content above is prompted by the following questions:

  • How would the results of the DESTINY-Breast09 trial impact your clinical practice?
  • What are your thoughts on the other trials mentioned above if they do result in positive results in PFS? How would they be applied to your treatment of different patient subsets?
Related Videos
Sagar D. Sardesai, MBBS
DB-12
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Ritu Salani, MD
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine